Skip to contentA
Agios Pharmaceuticals, Inc.
A
AGIOAgios Pharmaceuticals, Inc. Q2 2022 · 10-Q
Revenue$5.58M$5.58M— vs Q2 2021 Net Income-$91.81M-$91.81MN/M vs Q2 2021 EPS Diluted-$1.68-$1.68N/M vs Q2 2021 Operating Income-$97,640,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Agios Pharmaceuticals, Inc. · CIK 1439222 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$76,155,000N/M Margins · derivedOperating margin-1749.2%
Net margin-1644.7%
ended Jun 30, 2022 · filed Aug 4, 2022 · 35 d after period end